Question 1

Where do pregabalin and gabapentin fit in the anxiety treatment algorithm?

Accepted Answer

Pregabalin and gabapentin share a mechanism (alpha-2-delta calcium channel ligands), but their evidence bases and clinical positioning diverge sharply. Pregabalin has WFSBP Grade A evidence for GAD, faster onset than SSRIs (showing statistically significant group-level improvement vs placebo by approximately day 4; individual response varies), and no serotonergic side effects—making it a rational first-line alternative when SSRIs are contraindicated or poorly tolerated. Its effect size for GAD is 0.50, with an NNT of 5-8. Gabapentin, by contrast, has essentially no rigorous evidence for GAD (despite widespread off-label use) and failed a randomized panic disorder trial. The evidence for gabapentin in anxiety comes from a single 1999 SAD trial (effect size 0.78) and open-label reports, while controlled trials for GAD are essentially absent. Gabapentin is widely prescribed for anxiety due to its unscheduled status (legal convenience), not evidence-based superiority. Pregabalin is Schedule V (mild abuse potential), requiring more regulatory compliance, but this scheduling reflects documented abuse potential at supratherapeutic doses, not efficacy. For any alpha-2-delta ligand indication, pregabalin is the better-supported choice; gabapentin should not be used off-label for anxiety when pregabalin is available and feasible.

Question 2

Is pregabalin's efficacy comparable to SSRIs for GAD?

Accepted Answer

Pregabalin and gabapentin share a mechanism (alpha-2-delta calcium channel ligands), but their evidence bases and clinical positioning diverge sharply. Pregabalin has WFSBP Grade A evidence for GAD, faster onset than SSRIs (showing statistically significant group-level improvement vs placebo by approximately day 4; individual response varies), and no serotonergic side effects—making it a rational first-line alternative when SSRIs are contraindicated or poorly tolerated. Its effect size for GAD is 0.50, with an NNT of 5-8. Gabapentin, by contrast, has essentially no rigorous evidence for GAD (despite widespread off-label use) and failed a randomized panic disorder trial. The evidence for gabapentin in anxiety comes from a single 1999 SAD trial (effect size 0.78) and open-label reports, while controlled trials for GAD are essentially absent. Gabapentin is widely prescribed for anxiety due to its unscheduled status (legal convenience), not evidence-based superiority. Pregabalin is Schedule V (mild abuse potential), requiring more regulatory compliance, but this scheduling reflects documented abuse potential at supratherapeutic doses, not efficacy. For any alpha-2-delta ligand indication, pregabalin is the better-supported choice; gabapentin should not be used off-label for anxiety when pregabalin is available and feasible.

Question 3

How does pregabalin's mechanism differ from benzodiazepines?

Accepted Answer

Pregabalin and gabapentin share a mechanism (alpha-2-delta calcium channel ligands), but their evidence bases and clinical positioning diverge sharply. Pregabalin has WFSBP Grade A evidence for GAD, faster onset than SSRIs (showing statistically significant group-level improvement vs placebo by approximately day 4; individual response varies), and no serotonergic side effects—making it a rational first-line alternative when SSRIs are contraindicated or poorly tolerated. Its effect size for GAD is 0.50, with an NNT of 5-8. Gabapentin, by contrast, has essentially no rigorous evidence for GAD (despite widespread off-label use) and failed a randomized panic disorder trial. The evidence for gabapentin in anxiety comes from a single 1999 SAD trial (effect size 0.78) and open-label reports, while controlled trials for GAD are essentially absent. Gabapentin is widely prescribed for anxiety due to its unscheduled status (legal convenience), not evidence-based superiority. Pregabalin is Schedule V (mild abuse potential), requiring more regulatory compliance, but this scheduling reflects documented abuse potential at supratherapeutic doses, not efficacy. For any alpha-2-delta ligand indication, pregabalin is the better-supported choice; gabapentin should not be used off-label for anxiety when pregabalin is available and feasible.

Question 4

Is gabapentin evidence-based for anxiety or just commonly used off-label?

Accepted Answer

Pregabalin and gabapentin share a mechanism (alpha-2-delta calcium channel ligands), but their evidence bases and clinical positioning diverge sharply. Pregabalin has WFSBP Grade A evidence for GAD, faster onset than SSRIs (showing statistically significant group-level improvement vs placebo by approximately day 4; individual response varies), and no serotonergic side effects—making it a rational first-line alternative when SSRIs are contraindicated or poorly tolerated. Its effect size for GAD is 0.50, with an NNT of 5-8. Gabapentin, by contrast, has essentially no rigorous evidence for GAD (despite widespread off-label use) and failed a randomized panic disorder trial. The evidence for gabapentin in anxiety comes from a single 1999 SAD trial (effect size 0.78) and open-label reports, while controlled trials for GAD are essentially absent. Gabapentin is widely prescribed for anxiety due to its unscheduled status (legal convenience), not evidence-based superiority. Pregabalin is Schedule V (mild abuse potential), requiring more regulatory compliance, but this scheduling reflects documented abuse potential at supratherapeutic doses, not efficacy. For any alpha-2-delta ligand indication, pregabalin is the better-supported choice; gabapentin should not be used off-label for anxiety when pregabalin is available and feasible.

PsychHQ

Pregabalin vs Gabapentin for Anxiety: Why One Is Guideline-Endorsed and the Other Isn't